Aura Biosciences, Inc.

Oncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular

Oncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

CARGO Therapeutics Inc. executed the 21st initial public offering in the US by a biopharmaceutical company in 2023 and the fifth-largest so far this year when it grossed $281.3m from an offering of 1